Skip Navigation


JAC Advance Access first published online on March 10, 2006
This version published online on March 10, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl045
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/5/806    most recent
dkl045v2
dkl045v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barreiro, P.
Right arrow Articles by Soriano, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barreiro, P.
Right arrow Articles by Soriano, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading article

Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir

Pablo Barreiro 1 and Vincent Soriano 1 *

1 Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain

* To whom correspondence should be addressed.
Vincent Soriano, E-mail: vsoriano{at}dragonet.es


  Abstract

The combination of nucleos(t)ide analogues (NAs) is essential for the design of effective antiretroviral regimens. Although there are currently many options for the selection of such drug backbones, not all combinations display optimal results. As the number of these compounds has increased, it has become clear that the concomitant administration of certain NAs should be avoided due to high rates of toxicity and/or greater risk of virological failure. As an example, the combination of didanosine and tenofovir has recently been associated with a paradoxical depletion of CD4+ T cells in the face of complete viral suppression. Interference between the pathways leading to the intracellular activation of didanosine and tenofovir, and their blocking of the purine nucleoside phosphorylase, seems to explain this phenomenon.

Keywords: CD4+ T lymphocytes; purines; purine nucleoside phosphorylase.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
A Riordan and T Bugembe
Update on antiretroviral therapy
Arch. Dis. Child., January 1, 2009; 94(1): 70 - 74.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Torti, G. Lapadula, P. Barreiro, V. Soriano, S. Mandalia, A. De Silvestri, F. Suter, F. Maggiolo, A. Antinori, F. Antonucci, et al.
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
J. Antimicrob. Chemother., June 1, 2007; 59(6): 1141 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Schechter and S. H. Tuboi
Discordant immunological and virological responses to antiretroviral therapy
J. Antimicrob. Chemother., September 1, 2006; 58(3): 506 - 510.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. L. Anderson and T. N. Kakuda
Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir
J. Antimicrob. Chemother., July 1, 2006; 58(1): 220 - 221.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.